血液がん治療の世界市場：洞察、競合情勢、市場予測：2030年

世界の血液がん治療の市場規模は、2023年に565億9,000万米ドルとなりました。同市場は、2024年から2030年までの予測期間中に10.14％のCAGRで拡大し、2030年には1,008億米ドルに達すると予測されています。血液がん治療市場は、遺伝子やDNAの変異、発がん性物質への曝露、喫煙などによる血液がんの症例増加など、様々な要因のためにプラスの成長を示しています。さらに、座りっぱなしのライフスタイルや不健康な食事による糖尿病、高血圧、肥満、高脂血症などの生活習慣病の有病率の上昇も、血液がん治療市場の成長に貢献するでしょう。さらに、世界中で白血病とその治療に関する研究開発活動が活発化していることも、血液がん治療市場の成長を後押しするとみられています。

血液がん治療市場の主な促進要因の1つは、座りがちで不健康なライフスタイルの増加、遺伝子の突然変異、喫煙、アルコール、発がん性物質などへの暴露の増加などにより、世界中で血液がんの数値が増加していることです。

例えば、Cancer Fact Sheet 2022のデータによると、2023年には米国で新たに60,650人の白血病患者が診断され、24,000人がこの病気で死亡すると推定されています。さらに、米国保健福祉省の2022年の発表によると、2019年には米国で白血病患者72,714人が生活していると推定されています。

また、欧州委員会が発表したデータによると、白血病の発生率は欧州でも増加しています。この情報源によれば、2020年には、血液がんに罹患する人は11720人になると推定されています。同じ情報源によると、ドイツでは同じ年に13796人近くが血液がんに苦しんでいます。

当レポートでは、世界の血液がん治療市場について調査し、市場の概要とともに、適応症別、治療法別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 血液がん治療レポートのイントロダクション

第2章 血液がん治療のエグゼクティブサマリー

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 血液がん治療の主な要因分析

• 血液がん治療市場の促進要因
• 血液がん治療市場の抑制要因と課題
• 血液がん治療市場の機会

第5章 血液がん治療市場におけるポーターのファイブフォース分析

第6章 血液がん治療に対するCOVID-19の影響分析

第7章 血液がん治療市場の概要

• 適応症別
• 治療法別
• エンドユーザー別
• 地域別

第8章 血液がん治療の世界企業シェア分析-主要3～5社

第9章 血液がん治療の会社と製品プロファイル

• Pfizer Inc.
• F. Hoffmann-LA Roche Ltd
• Sanofi SA
• Bristol-Myers Squibb Company
• AbbVie Inc
• Novartis AG
• GlaxoSmithKline PLC
• Amgen Inc.
• Takeda Pharmaceutical Co. Ltd
• Johnson & Johnson
• Incyte Corporation
• AstraZeneca PLC
• Celldex Therapeutics Inc.
• Kite Pharma (Gilead Sciences)
• Atara Biotherapeutics
• Celgene Corporation
• Astellas
• Eli Lilly and Company
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC.

第10章 KOL の見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: COVID-19 Impact Analysis
• Table 3: Haematological Cancer (Blood Cancer) Therapeutics in Global (2021-2030)
• Table 4: Haematological Cancer (Blood Cancer) Therapeutics in Global by Indication (2021-2030)
• Table 5: Haematological Cancer (Blood Cancer) Therapeutics in Global by Therapy (2021-2030)
• Table 6: Haematological Cancer (Blood Cancer) Therapeutics in Global by End-User (2021-2030)
• Table 7: Haematological Cancer (Blood Cancer) Therapeutics in Global by Geography (2021-2030)
• Table 8: Haematological Cancer (Blood Cancer) Therapeutics in North America (2021-2030)
• Table 9: Haematological Cancer (Blood Cancer) Therapeutics in North America by Country (2021-2030)
• Table 10: Haematological Cancer (Blood Cancer) Therapeutics in the US (2021-2030)
• Table 11: Haematological Cancer (Blood Cancer) Therapeutics in Canada (2021-2030)
• Table 12: Haematological Cancer (Blood Cancer) Therapeutics in Mexico (2021-2030)
• Table 13: Haematological Cancer (Blood Cancer) Therapeutics in Europe (2021-2030)
• Table 14: Haematological Cancer (Blood Cancer) Therapeutics in Europe by Country (2021-2030)
• Table 15: Haematological Cancer (Blood Cancer) Therapeutics in France (2021-2030)
• Table 16: Haematological Cancer (Blood Cancer) Therapeutics in Germany (2021-2030)
• Table 17: Haematological Cancer (Blood Cancer) Therapeutics in the United Kingdom (2021-2030)
• Table 18: Haematological Cancer (Blood Cancer) Therapeutics in Italy (2021-2030)
• Table 19: Haematological Cancer (Blood Cancer) Therapeutics in Spain (2021-2030)
• Table 20: Haematological Cancer (Blood Cancer) Therapeutics in Russia (2021-2030)
• Table 21: Haematological Cancer (Blood Cancer) Therapeutics in Rest of Europe (2021-2030)
• Table 22: Haematological Cancer (Blood Cancer) Therapeutics in APAC (2021-2030)
• Table 23: Haematological Cancer (Blood Cancer) Therapeutics in APAC by Country (2021-2030)
• Table 24: Haematological Cancer (Blood Cancer) Therapeutics in China (2021-2030)
• Table 25: Haematological Cancer (Blood Cancer) Therapeutics in Japan (2021-2030)
• Table 26: Haematological Cancer (Blood Cancer) Therapeutics in India (2021-2030)
• Table 27: Haematological Cancer (Blood Cancer) Therapeutics in Australia (2021-2030)
• Table 28: Haematological Cancer (Blood Cancer) Therapeutics in South Korea (2021-2030)
• Table 29: Haematological Cancer (Blood Cancer) Therapeutics in Rest of APAC (2021-2030)
• Table 30: Haematological Cancer (Blood Cancer) Therapeutics in Rest of World (2021-2030)
• Table 31: Haematological Cancer (Blood Cancer) Therapeutics in RoW by Region (2021-2030)
• Table 32: Haematological Cancer (Blood Cancer) Therapeutics in Middle East (2021-2030)
• Table 33: Haematological Cancer (Blood Cancer) Therapeutics in Africa (2021-2030)
• Table 34: Haematological Cancer (Blood Cancer) Therapeutics in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: COVID-19 Impact Analysis
• Figure 3: Haematological Cancer (Blood Cancer) Therapeutics in Global (2021-2030)
• Figure 4: Haematological Cancer (Blood Cancer) Therapeutics in Global by Indication (2021-2030)
• Figure 5: Haematological Cancer (Blood Cancer) Therapeutics in Global by Therapy (2021-2030)
• Figure 6: Haematological Cancer (Blood Cancer) Therapeutics in Global by End-User (2021-2030)
• Figure 7: Haematological Cancer (Blood Cancer) Therapeutics in Global by Geography (2021-2030)
• Figure 8: Haematological Cancer (Blood Cancer) Therapeutics in North America (2021-2030)
• Figure 9: Haematological Cancer (Blood Cancer) Therapeutics in North America by Country (2021-2030)
• Figure 10: Haematological Cancer (Blood Cancer) Therapeutics in the US (2021-2030)
• Figure 11: Haematological Cancer (Blood Cancer) Therapeutics in Canada (2021-2030)
• Figure 12: Haematological Cancer (Blood Cancer) Therapeutics in Mexico (2021-2030)
• Figure 13: Haematological Cancer (Blood Cancer) Therapeutics in Europe (2021-2030)
• Figure 14: Haematological Cancer (Blood Cancer) Therapeutics in Europe by Country (2021-2030)
• Figure 15: Haematological Cancer (Blood Cancer) Therapeutics in France (2021-2030)
• Figure 16: Haematological Cancer (Blood Cancer) Therapeutics in Germany (2021-2030)
• Figure 17: Haematological Cancer (Blood Cancer) Therapeutics in the United Kingdom (2021-2030)
• Figure 18: Haematological Cancer (Blood Cancer) Therapeutics in Italy (2021-2030)
• Figure 19: Haematological Cancer (Blood Cancer) Therapeutics in Spain (2021-2030)
• Figure 20: Haematological Cancer (Blood Cancer) Therapeutics in Russia (2021-2030)
• Figure 21: Haematological Cancer (Blood Cancer) Therapeutics in Rest of Europe (2021-2030)
• Figure 22: Haematological Cancer (Blood Cancer) Therapeutics in APAC (2021-2030)
• Figure 23: Haematological Cancer (Blood Cancer) Therapeutics in APAC by Country (2021-2030)
• Figure 24: Haematological Cancer (Blood Cancer) Therapeutics in China (2021-2030)
• Figure 25: Haematological Cancer (Blood Cancer) Therapeutics in Japan (2021-2030)
• Figure 26: Haematological Cancer (Blood Cancer) Therapeutics in India (2021-2030)
• Figure 27: Haematological Cancer (Blood Cancer) Therapeutics in Australia (2021-2030)
• Figure 28: Haematological Cancer (Blood Cancer) Therapeutics in South Korea (2021-2030)
• Figure 29: Haematological Cancer (Blood Cancer) Therapeutics in Rest of APAC (2021-2030)
• Figure 30: Haematological Cancer (Blood Cancer) Therapeutics in Rest of World (2021-2030)
• Figure 31: Haematological Cancer (Blood Cancer) Therapeutics in RoW by Region (2021-2030)
• Figure 32: Haematological Cancer (Blood Cancer) Therapeutics in Middle East (2021-2030)
• Figure 33: Haematological Cancer (Blood Cancer) Therapeutics in Africa (2021-2030)
• Figure 34: Haematological Cancer (Blood Cancer) Therapeutics in South America (2021-2030)
• Figure 35: Market Drivers
• Figure 36: Market Barriers
• Figure 37: Marker Opportunities
• Figure 38: PORTER'S Five Force Analysis

Hematological Cancer (Blood Cancer) Therapeutics By Indication (Leukemia, Lymphoma, And Myeloma), By Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, And Other Therapies), By End-User (Hospital Pharmacies, Retail Pharmacy, And Others) and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of blood cancer and increasing prevalence of lifestyle disorders worldwide

The global hematological cancer or blood cancer therapeutic market was valued at USD 56.59 billion in 2023, growing at a CAGR of 10.14% during the forecast period from 2024 to 2030 to reach USD 100.80 billion by 2030. The hematological cancer (blood cancer) therapeutics market is witnessing positive growth owing to various factors such as rising cases of blood cancer due to gene or DNA mutation, exposure to carcinogenic substances, smoking, among others. Additionally, increasing prevalence of lifestyle disorders such as diabetes, hypertension, obesity, hyperlipidemia, and others due to sedentary lifestyle & unhealthy eating will also contribute in the growth of hematological cancer therapeutics market. Further, increasing research and development activities in arena of leukemia and its treatment across the globe will also aid in the growth of the hematological cancer (blood cancer) therapeutics market. Therefore, the market for hematological cancer (blood cancer) therapeutics is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.

Hematological Cancer (Blood Cancer) Therapeutics Dynamics:

One of the main driver for the hematological cancer (blood cancer) therapeutics market is the increasing figures of blood cancer across the globe due to the rising sedentary and unhealthy lifestyle, gene mutations, increasing exposure to smoking, alcohol, carcinogenic substances, among others.

For instance, as per the data given by Cancer Fact Sheet 2022, it is estimated that in the year 2023, an estimated 60,650 new cases of leukaemia will be diagnosed in the United States and 24,000 people will die from the disease. Moreover, as per the US department of Health and Human Services, 2022, it was estimated that in the year 2019, 72,714 people living with leukaemia in the United States.

Also, as per the data published by European Commission, the incidence of leukaemia is also increasing in the Europe. The source estimated that in the year 2020, there were total 11720 people suffering from blood cancer. As per the same source, in the Germany, nearly 13796 people suffered from blood cancers in the same year.

Additionally, the Blood Cancer UK, 2022, stated that there were about 250,000 people living with blood cancer in the United Kingdom, in the year 2023. The source also stated that one in every 16 men and one in every 22 women will develop it at some point in their lives.

Thus, the increasing prevalence of blood cancer in the different regions in the world will increase the demand of its therapy, thereby spurring the overall market growth of haematological cancer therapeutics.

Further, smoking, radiation exposure, and exposure to certain chemicals have all been linked to the increased risk of some types of blood cancers. Epstein-Barr virus, HIV and human T-cell lymphoma/leukaemia virus infections are also risk factors for developing lymphomas and leukaemia. Thus, increased exposure to any of the above factor will increase the number of cases of blood cancer, ultimately increasing the demand of haematological cancer therapeutics in the upcoming years. According to the World Health Organization (WHO) 2022, in 2020, 22.3% of the global population used tobacco, 36.7% of all men and 7.8% of the world's women. Thus, the increased consumption of tobacco will further increase the prevalence of blood cancer, ultimately increasing the demand of blood cancer therapeutics in the forecast period.

Therefore, the factors stated above collectively will drive the overall hematological cancer or blood cancer therapeutics during the forecast period from 2024-2030.

However, high cost of therapy, serious adverse drug reactions of therapy, and others, can hinder the global hematological cancer (blood cancer) therapeutics market growth.

The COVID-19 pandemic has slightly impacted the market for hematological cancer (blood cancer) therapy. The outbreak of the pandemic led to the cancellation of outpatient visits and the suspension of non-emergency hospitals and procedures for chronic disorders such as cancers, diabetes, cardiovascular disorders, others. This resulted in the reduced number of patients for the routine treatments of the above mentioned disorders. However, vaccine development of COVID-19 has produced the process of economic recovery with the easing of lockdown restrictions and the return of normalcy in the economic landscape which has initiated the process of resumption of regular healthcare services such as outpatient's visits, thereby bringing the demand for products on track in the hematological cancer (blood cancer) therapy market.

Hematological Cancer (Blood Cancer) Therapeutics Segment Analysis:

Hematological Cancer (Blood Cancer) Therapeutics By Indication (Leukemia, Lymphoma, and Myeloma), Therapy (Chemotherapy, Immunotherapy, Targeted Therapy, and Other Therapies), End-User (Hospital Pharmacies, Retail Pharmacy, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the therapy segment of the hematological cancer (blood cancer) therapeutics, the chemotherapy market is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing advantages offered by the segment.

Chemotherapy is one of the major therapy for the treatment of various cancers including leukemia. Chemotherapy may shrink the cancer cells present in the blood or slow down its growth, which may help the patients live longer and help with the symptoms. For a small number of people with borderline blood cancer, chemotherapy may shrink the cancer enough to make surgery to remove the cancer possible. Thus, making it an apt treatment for patients with borderline blood cancers.

Additionally, chemotherapy reduces pain and other problems caused by the bone marrow tumor and can cure the blood cancer completely, if treated at a proper time. Furthermore, the chemotherapy treatment can be used for all the age groups and for both the genders in the same manner. Due to this fact, chemotherapy is one of the most popular therapy among all the other therapies.

In chemotherapy, a combination of drugs is used to destroy as many leukemia cells as possible and bring blood counts to normal. Then, intensification chemotherapy is intended to destroy remaining leukemia cells that cannot be seen in the blood or bone marrow.

Thus, owing to the various advantages and applications offered by chemotherapy, there will be an increase in the demand chemotherapy, which in turn will drive the hematological cancer (blood cancer) therapy market growth in the forecast period from 2022 - 2028.

North America is expected to dominate the overall Hematological Cancer (Blood Cancer) Therapeutics:

Among all the regions, North America is expected to dominate the global hematological cancer (blood cancer) therapeutics in the year 2023 and is expected to do the same during the forecast period from 2024-2030.

Increasing research & developmental activities such as, therapy development for blood cancer and the rising prevalence of blood cancer due to gene mutations, smoking, radiation, viruses, cancer-causing chemicals (carcinogens), hormones, unhealthy lifestyle, and a lack of exercise will increase the demand for hematological cancer (blood cancer) therapy in North America, leading to a rise in the overall hematological cancer (blood cancer) therapy market growth.

For instance, according the American Cancer Society 2022, it was estimated that in 2022, 60,650 new cases of leukemia will be diagnosed in the US and 24,000 people will die from the disease.

Additionally, according to Leukemia & Lymphoma Society 2022, an estimated combined total of 186,400 people in the United States were diagnosed with leukemia, lymphoma or myeloma in 2022. As per the same source, approximately every 3 minutes, one person in the United States is diagnosed with leukemia, lymphoma or myeloma. The above source, also stated that nearly 1,519,907 people in the United States were living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs) in the year 2023.

Further, as per the Canadian Cancer Society 2022, the incidence of leukemia in Canada and in males was reported to be 3.4% and in women was nearly 2.4%. On the other hand, according to the Global Cancer Observatory 2022, the incidence of leukemia in the year 2020 was found to be 6,955. Thus, the above mentioned sources states that the prevalence of blood cancer is quite high in all of the regions of North America.

Thus, the increasing prevalence of blood cancer across the North America will increase the demand of hematological cancer (blood cancer) therapy, thereby propelling the overall market growth in the North America during the forecast period.

Hematological Cancer (Blood Cancer) Therapeutics Key Players:

Some of the key market players operating in the hematological cancer (blood cancer) therapeutics include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and others.

Recent Developmental Activities in the Hematological Cancer (Blood Cancer) Therapeutics:

In June 2022, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating blood cancer named TNB-383B.

In April 2022, U.S. Food and Drug Administration (FDA) had announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of blood cancer.

Key Takeaways from the Hematological Cancer (Blood Cancer) Therapeutics Report Study

• Market size analysis for current hematological cancer (blood cancer) therapeutics (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the hematological cancer (blood cancer) therapeutics
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
• Key companies dominating the global hematological cancer (blood cancer) therapeutics
• Various opportunities are available for the other competitor in the hematological cancer (blood cancer) therapeutics space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current hematological cancer (blood cancer) therapeutics scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hematological cancer (blood cancer) therapeutics growth in the coming future?

Target Audience who can be benefited from this Hematological Cancer (Blood Cancer) Therapeutics Report Study

• Hematological cancer (blood cancer) therapeutics providers
• Research organizations and consulting companies
• Hematological cancer (blood cancer) therapeutics -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in hematological cancer (blood cancer) therapeutics
• Various end-users who want to know more about the hematological cancer (blood cancer) therapeutics and the latest technological developments in the hematological cancer (blood cancer) therapeutics

Frequently Asked Questions for Hematological Cancer (Blood Cancer) Therapeutics:

1. What is Haematological Cancer (Blood Cancer) Therapeutics?

Haematological cancer or blood cancer therapeutics are the therapies and devices available in the market used for the treatment or management of the blood cancers.

2. What is the market for Global Haematological Cancer (Blood Cancer) Therapeutics?

The global hematological cancer or blood cancer therapeutic market was valued at USD 56.59 billion in 2023, growing at a CAGR of 10.14% during the forecast period from 2024 to 2030 to reach USD 100.80 billion by 2030.

3. What are the drivers for the Global Haematological Cancer (Blood Cancer) Therapeutics?

The hematological cancer (blood cancer) therapeutics is witnessing a positive market growth owing to the factors such as rising prevalence of blood cancers, increasing prevalence of lifestyle disorders, increasing research and development activities in arena of leukaemia and its treatment, and the rise in the regulatory approvals for hematological cancer (blood cancer) therapeutics.

4. Who are the key players operating in the Haematological Cancer (Blood Cancer) Therapeutics?

Some of the key market players operating in the Haematological Cancer (Blood Cancer) Therapeutics include Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC., and others.

5. Which region has the highest share in Haematological Cancer (Blood Cancer) Therapeutics?

North America is expected to dominate the global Haematological Cancer (Blood Cancer) Therapeutics. Factors contributing to the growth are the increasing incidence of blood cancers, and the rise in the regulatory approvals for hematological cancer (blood cancer) therapies, which are contributing to the growth of the hematological cancer (blood cancer) therapeutics in the North American region.

Table of Contents

1.Hematological Cancer (Blood Cancer) Therapeutics Report Introduction

2. Hematological Cancer (Blood Cancer) Therapeutics Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The US
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Hematological Cancer (Blood Cancer) Therapeutics Key Factors Analysis

• 4.1. Hematological Cancer (Blood Cancer) Therapeutics Drivers
  • 4.1.1. Rising incidence of blood cancers
  • 4.1.2. Increasing prevalence of lifestyle disorders
  • 4.1.3. Increasing research and development activities in arena of leukemia and its treatment
• 4.2. Hematological Cancer (Blood Cancer) Therapeutics Restraints And Challenges
  • 4.2.1. High cost of therapy
  • 4.2.2. Serious Adverse Drug Reactions of Therapy
• 4.3. Hematological Cancer (Blood Cancer) Therapeutics Opportunities
  • 4.3.1. Advancement in immunohistochemistry (IHC) which can be useful for the development of leukemia therapy
  • 4.3.2. Increasing demand of targeted therapies

5. Hematological Cancer (Blood Cancer) Therapeutics Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Hematological Cancer (Blood Cancer) Therapeutics

7. Hematological Cancer (Blood Cancer) Therapeutics Layout

• 7.1. By Indication
  • 7.1.1. Leukemia
  • 7.1.2. Lymphoma
  • 7.1.3. Myeloma
• 7.2. By Therapy
  • 7.2.1. Chemotherapy
  • 7.2.2. Immunotherapy
  • 7.2.3. Targeted Therapy
  • 7.2.4. Other Therapies
• 7.3. By End-User
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Retail Pharmacy
  • 7.3.3. Others
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.1.2. Canada Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.1.3. Mexico Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.2. Germany Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.3. United Kingdom Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.4. Italy Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.5. Spain Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.6. Russia Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.2.7. Rest of Europe Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.3.2. Japan Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.3.3. India Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.3.4. Australia Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.3.5. South Korea Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.4.2. Africa Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)
    • 7.4.4.3. South America Hematological Cancer (Blood Cancer) Therapeutics Market Size in USD Million (2021-2030)

8. Hematological Cancer (Blood Cancer) Therapeutics Global Company Share Analysis - Key 3-5 Companies

9. Hematological Cancer (Blood Cancer) Therapeutics Company and Product Profiles

• 9.1. Pfizer Inc.
  • 9.1.1. Company Overview
  • 9.1.2. Company Snapshot
  • 9.1.3. Financial Overview
  • 9.1.4. Product Listing
  • 9.1.5. Entropy
• 9.2. F. Hoffmann-LA Roche Ltd
  • 9.2.1. Company Overview
  • 9.2.2. Company Snapshot
  • 9.2.3. Financial Overview
  • 9.2.4. Product Listing
  • 9.2.5. Entropy
• 9.3. Sanofi SA
  • 9.3.1. Company Overview
  • 9.3.2. Company Snapshot
  • 9.3.3. Financial Overview
  • 9.3.4. Product Listing
  • 9.3.5. Entropy
• 9.4. Bristol-Myers Squibb Company
  • 9.4.1. Company Overview
  • 9.4.2. Company Snapshot
  • 9.4.3. Financial Overview
  • 9.4.4. Product Listing
  • 9.4.5. Entropy
• 9.5. AbbVie Inc
  • 9.5.1. Company Overview
  • 9.5.2. Company Snapshot
  • 9.5.3. Financial Overview
  • 9.5.4. Product Listing
  • 9.5.5. Entropy
• 9.6. Novartis AG
  • 9.6.1. Company Overview
  • 9.6.2. Company Snapshot
  • 9.6.3. Financial Overview
  • 9.6.4. Product Listing
  • 9.6.5. Entropy
• 9.7. GlaxoSmithKline PLC
  • 9.7.1. Company Overview
  • 9.7.2. Company Snapshot
  • 9.7.3. Financial Overview
  • 9.7.4. Product Listing
  • 9.7.5. Entropy
• 9.8. Amgen Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Snapshot
  • 9.8.3. Financial Overview
  • 9.8.4. Product Listing
  • 9.8.5. Entropy
• 9.9. Takeda Pharmaceutical Co. Ltd
  • 9.9.1. Company Overview
  • 9.9.2. Company Snapshot
  • 9.9.3. Financial Overview
  • 9.9.4. Product Listing
  • 9.9.5. Entropy
• 9.10. Johnson & Johnson
  • 9.10.1. Company Overview
  • 9.10.2. Company Snapshot
  • 9.10.3. Financial Overview
  • 9.10.4. Product Listing
  • 9.10.5. Entropy
• 9.11. Incyte Corporation
  • 9.11.1. Company Overview
  • 9.11.2. Company Snapshot
  • 9.11.3. Financial Overview
  • 9.11.4. Product Listing
  • 9.11.5. Entropy
• 9.12. AstraZeneca PLC
  • 9.12.1. Company Overview
  • 9.12.2. Company Snapshot
  • 9.12.3. Financial Overview
  • 9.12.4. Product Listing
  • 9.12.5. Entropy
• 9.13. Celldex Therapeutics Inc.
  • 9.13.1. Company Overview
  • 9.13.2. Company Snapshot
  • 9.13.3. Financial Overview
  • 9.13.4. Product Listing
  • 9.13.5. Entropy
• 9.14. Kite Pharma (Gilead Sciences)
  • 9.14.1. Company Overview
  • 9.14.2. Company Snapshot
  • 9.14.3. Financial Overview
  • 9.14.4. Product Listing
  • 9.14.5. Entropy
• 9.15. Atara Biotherapeutics
  • 9.15.1. Company Overview
  • 9.15.2. Company Snapshot
  • 9.15.3. Financial Overview
  • 9.15.4. Product Listing
  • 9.15.5. Entropy
• 9.16. Celgene Corporation
  • 9.16.1. Company Overview
  • 9.16.2. Company Snapshot
  • 9.16.3. Financial Overview
  • 9.16.4. Product Listing
  • 9.16.5. Entropy
• 9.17. Astellas
  • 9.17.1. Company Overview
  • 9.17.2. Company Snapshot
  • 9.17.3. Financial Overview
  • 9.17.4. Product Listing
  • 9.17.5. Entropy
• 9.18. Eli Lilly and Company
  • 9.18.1. Company Overview
  • 9.18.2. Company Snapshot
  • 9.18.3. Financial Overview
  • 9.18.4. Product Listing
  • 9.18.5. Entropy
• 9.19. Sun Pharmaceutical Industries Ltd.
  • 9.19.1. Company Overview
  • 9.19.2. Company Snapshot
  • 9.19.3. Financial Overview
  • 9.19.4. Product Listing
  • 9.19.5. Entropy
• 9.20. Amneal Pharmaceuticals LLC.
  • 9.20.1. Company Overview
  • 9.20.2. Company Snapshot
  • 9.20.3. Financial Overview
  • 9.20.4. Product Listing
  • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us